Bank Julius Baer & Co. Ltd Zurich Purchases 73,200 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Bank Julius Baer increased its Bristol Myers Squibb stake by 6%, purchasing 73,200 shares to own 1.29 million shares valued at approximately $80.4 million. Institutional investors and hedge funds collectively hold 76.41% of BMY.
• Bristol Myers Squibb reported third-quarter revenue of $13.07 billion and adjusted EPS of $1.35, surpassing analyst estimates, while raising its 2026 revenue outlook to roughly $50 billion. However, adjusted earnings declined year over year, and weaker-than-expected Opdivo sales and upcoming patent expirations remain concerns.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $65.46. The company also announced a quarterly dividend of $0.63 per share, representing a 4.0% annualized yield.

Bank Julius Baer & Co. Ltd Zurich increased its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 6.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,286,191 shares of the biopharmaceutical company's stock after acquiring an additional 73,200 shares during the period. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.06% of Bristol Myers Squibb worth $80,361,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. BlackRock Inc. raised its position in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after buying an additional 8,702,106 shares during the last quarter. State Street Corp increased its holdings in Bristol Myers Squibb by 7.3% in the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company's stock valued at $6,093,755,000 after buying an additional 7,192,724 shares during the period. Primecap Management Co. CA acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Bristol Myers Squibb by 0.5% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company's stock valued at $1,315,984,000 after purchasing an additional 119,690 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Bristol Myers Squibb by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company's stock valued at $1,137,847,000 after acquiring an additional 520,330 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BMY. Citigroup reiterated a "neutral" rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Argus upgraded Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 price target for the company in a research note on Wednesday, August 5th. JPMorgan Chase & Co. raised their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an "overweight" rating in a report on Friday, July 31st. William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research report on Monday, October 12th. Finally, BMO Capital Markets reiterated a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $65.46.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported third-quarter adjusted EPS of $1.35 and revenue of $13.07 billion, exceeding consensus estimates of $1.10 and $12.72 billion, respectively. Revenue increased 6.9% year over year. Bristol Myers Squibb Q3 revenue report
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs—grew 12% to $7.7 billion, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
• Positive Sentiment: Barclays maintained its Buy rating, while management pointed to pipeline progress, cancer-trial data and increased use of artificial intelligence in drug research as potential longer-term catalysts. Barclays maintains Buy rating
• Neutral Sentiment: The improved sales outlook is largely a revenue story: deal-related and higher in-process research and development charges contributed to a reduction in 2026 EPS guidance, and adjusted earnings fell from $1.63 a year earlier to $1.35. BMY earnings and guidance report
• Negative Sentiment: Opdivo sales came in below expectations, highlighting launch execution risks and the continuing challenge of replacing revenue from aging blockbuster drugs. Bristol Myers Opdivo sales report
• Negative Sentiment: Morgan Stanley cut its price target from $41 to $40 and reiterated an Underweight rating, implying substantial downside from the current trading level. Morgan Stanley BMY rating
• Negative Sentiment: A separate analysis downgraded BMY, arguing that progress from newer medicines may not fully overcome the company’s upcoming patent cliffs. Bristol Myers patent-cliff analysis

Insiders Place Their Bets

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.05% of the company's stock.

Bristol Myers Squibb Stock Down 0.0%

NYSE BMY opened at $62.46 on Monday. The firm has a 50-day simple moving average of $62.80 and a 200 day simple moving average of $59.94. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. The stock has a market cap of $127.67 billion, a PE ratio of 13.85, a PEG ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a twelve month low of $45.20 and a twelve month high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The firm had revenue of $13.07 billion for the quarter, compared to analysts' expectations of $12.72 billion. During the same quarter in the previous year, the firm posted $1.63 earnings per share. The company's revenue was up 6.9% on a year-over-year basis. On average, research analysts forecast that Bristol Myers Squibb Company will post 6.40 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is 55.88%.

Bristol Myers Squibb Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.